Literature DB >> 22355058

Targeting the interleukin-6/Jak/stat pathway in human malignancies.

Pasquale Sansone1, Jacqueline Bromberg.   

Abstract

The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling. Since this time, more than 2,500 articles have been published demonstrating the importance of this pathway in virtually all malignancies. Although there are dozens of cytokines and cytokine receptors, four Jaks, and seven Stats, it seems that interleukin-6-mediated activation of Stat3 is a principal pathway implicated in promoting tumorigenesis. This transcription factor regulates the expression of numerous critical mediators of tumor formation and metastatic progression. This review will examine the relative importance and function of this pathway in nonmalignant conditions as well as malignancies (including tumor intrinsic and extrinsic), the influence of other Stats, the development of inhibitors to this pathway, and the potential role of inhibitors in controlling or eradicating cancers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22355058      PMCID: PMC3341105          DOI: 10.1200/JCO.2010.31.8907

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  184 in total

1.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Cell signaling. Stat acetylation--a key facet of cytokine signaling?

Authors:  John J O'Shea; Yuka Kanno; Xiaomin Chen; David E Levy
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

Review 3.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

4.  Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Authors:  Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

5.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

6.  Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice.

Authors:  Norio Horiguchi; Fouad Lafdil; Andrew M Miller; Ogyi Park; Hua Wang; Mohanraj Rajesh; Partha Mukhopadhyay; Xin Yuan Fu; Pal Pacher; Bin Gao
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.

Authors:  Yaping Sun; Y Eugene Chin; Elizabeth Weisiger; Chelsea Malter; Isao Tawara; Tomomi Toubai; Erin Gatza; Paolo Mascagni; Charles A Dinarello; Pavan Reddy
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

9.  Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells.

Authors:  Masako Saito; Masayuki Nagasawa; Hidetoshi Takada; Toshiro Hara; Shigeru Tsuchiya; Kazunaga Agematsu; Masafumi Yamada; Nobuaki Kawamura; Tadashi Ariga; Ikuya Tsuge; Shigeaki Nonoyama; Hajime Karasuyama; Yoshiyuki Minegishi
Journal:  J Exp Med       Date:  2011-02-07       Impact factor: 14.307

10.  Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility.

Authors:  Debra L Silver; Honami Naora; Jinsong Liu; Wenjun Cheng; Denise J Montell
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

View more
  215 in total

Review 1.  Molecular Pathways: Targeting the Microenvironment of Liver Metastases.

Authors:  Simon Milette; Jason K Sicklick; Andrew M Lowy; Pnina Brodt
Journal:  Clin Cancer Res       Date:  2017-06-14       Impact factor: 12.531

2.  Investigation of JAKs/STAT-3 in lipopolysaccharide-induced intestinal epithelial cells.

Authors:  L Fu; L-W Wei; M-D Zhao; J-L Zhu; S-Y Chen; X-B Jia; S-J Lai
Journal:  Clin Exp Immunol       Date:  2016-08-01       Impact factor: 4.330

Review 3.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 4.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

5.  Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.

Authors:  Nicholas Don-Doncow; Zilma Escobar; Martin Johansson; Sven Kjellström; Victor Garcia; Eduardo Munoz; Olov Sterner; Anders Bjartell; Rebecka Hellsten
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

Review 6.  Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.

Authors:  Oana Draghiciu; Joyce Lubbers; Hans W Nijman; Toos Daemen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

7.  Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity.

Authors:  Tiancen Hu; Jennifer E Yeh; Luca Pinello; Jaison Jacob; Srinivas Chakravarthy; Guo-Cheng Yuan; Rajiv Chopra; David A Frank
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

8.  Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment.

Authors:  Amir Sonnenblick; Tamar Zahavi
Journal:  Biomed Rep       Date:  2017-03-30

9.  Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.

Authors:  Braden C McFarland; G Kenneth Gray; Susan E Nozell; Suk W Hong; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2013-02-05       Impact factor: 5.852

Review 10.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.